FOSUN HEALTH Logo

Pancreatic Cancer Treatment

catalogue

Pancreatic Cancer Treatment

Pancreatic Cancer Treatment

For pancreatic cancer the treatment question is not only what to give but in what order. The resectability category decides whether an operation comes first, comes after chemotherapy, or does not come at all.

Treatment at a glance

The plan follows resectability rather than the stage number, and the sequence is the part patients find most surprising:

  • Resectable — surgery first (pancreaticoduodenectomy or distal pancreatectomy), then adjuvant chemotherapy for several months. Some teams now use chemotherapy before surgery here as well.
  • Borderline resectable — chemotherapy first, usually FOLFIRINOX or gemcitabine with nab-paclitaxel, then re-imaging. If the tumour has pulled away from the vessels, an operation is planned; if it has not, the treatment continues as for locally advanced disease.
  • Locally advanced — systemic chemotherapy, with radiotherapy considered for local control and for pain. Surgery is revisited only if the tumour regresses far enough to allow a margin-negative resection.
  • Metastatic — combination chemotherapy, with molecular testing to determine whether a maintenance PARP inhibitor, an immune checkpoint inhibitor or a matched targeted drug applies.
  • Jaundice before anything else — a blocked bile duct is usually relieved with a stent first, because jaundice impairs liver function, worsens nutrition and makes chemotherapy harder to tolerate.
  • Pain that is not controlled by tablets — a coeliac plexus block or neurolysis can be performed at the time of endoscopic ultrasound, and it is under-used rather than experimental.

One consequence of this ordering is worth stating plainly: a patient who is told they need chemotherapy before surgery has not been refused an operation. The chemotherapy is being used to make the operation safer and more likely to remove the tumour completely.

Surgery: what the operations are

Two operations account for almost all pancreatic cancer surgery, and which one applies depends on where the tumour sits:

  • Pancreaticoduodenectomy (the Whipple operation) — for tumours in the head of the gland. The head of the pancreas, the duodenum, the distal stomach in some variants, the bile duct and the gallbladder are removed, and the gut is rejoined to the pancreas, the bile duct and the stomach. It is the most demanding of the standard abdominal operations, and complication rates fall sharply with volume.
  • Distal pancreatectomy with splenectomy — for tumours in the body and tail. The spleen is usually removed with the distal pancreas because the splenic vessels run through the gland.
  • Vascular resection and reconstruction — where the tumour abuts or narrows the portal or superior mesenteric vein, that segment can be resected and reconstructed. It adds time and risk to the operation, and it converts a subset of borderline cases into operable ones.
  • Lymph node clearance — the standard operation includes removal of the regional nodes around the gland, which is both part of the staging and part of the treatment.
  • What surgery cannot do — if the tumour encases a major artery, a margin-negative operation is not achievable, and an operation that leaves tumour behind does not improve survival while carrying the full risk of the procedure.

Recovery takes weeks rather than days, and the two complications that dominate the post-operative course are a leak from the pancreatic join and delayed emptying of the stomach. Both are managed with drainage, nutrition support and time, and both are reasons why the operation should be done where it is done often.

Chemotherapy before surgery

Giving chemotherapy before an operation — neoadjuvant treatment — has become standard for borderline resectable disease and is increasingly used for resectable tumours as well. The reasoning is not that the operation is being delayed but that it is being made more likely to succeed.

  • It can pull the tumour away from a vessel — the main purpose in borderline resectable disease, where the tumour touching a vein may recede enough for a clean plane.
  • It tests the biology — if the disease progresses during chemotherapy, an operation would not have controlled it either, and the patient has been spared a major procedure with no benefit.
  • It treats what cannot be seen — micrometastatic disease is the usual reason a technically successful operation is followed by recurrence, and systemic treatment given first addresses it earlier.
  • It is better tolerated before surgery than after — recovery from a pancreatic resection makes full-dose chemotherapy harder to deliver, which is a practical argument as much as a biological one.

The regimen is usually FOLFIRINOX, or gemcitabine with nab-paclitaxel where the first is not suitable, and it is given for a defined number of cycles followed by re-imaging rather than indefinitely. The decision to operate is then remade on the new scans, which is why the restaging CT is not a formality.

Chemotherapy after surgery

After a resection, chemotherapy is given for several months even when the operation has gone well and the nodes look clear. This is the single most established treatment in pancreatic cancer, and the reason is that the disease recurs systemically far more often than it recurs locally.

  • Modified FOLFIRINOX — used where the patient is fit enough, and the regimen with the clearest supporting evidence in the adjuvant setting.
  • Gemcitabine with capecitabine — an alternative where FOLFIRINOX is not suitable, and gentler on a patient recovering from major surgery.
  • Timing — treatment usually begins once recovery allows, commonly within the first two months after the operation, and the intended duration is six months where tolerated.
  • Nutrient and enzyme support — pancreatic enzyme replacement and dietetic input run alongside the chemotherapy rather than being an afterthought, because weight loss limits how much treatment can be given.

If chemotherapy was given before the operation, the post-operative plan takes that into account and is decided at the multidisciplinary meeting rather than by default. What is not in question is that some form of systemic treatment follows a resection in almost every case.

Systemic treatment for advanced disease

When the tumour is locally advanced or metastatic, chemotherapy is the mainstay, and the choice is made on fitness, on the molecular profile and on what the patient can tolerate over months rather than weeks:

  • FOLFIRINOX — a four-drug combination, and the most active first-line regimen for patients who are fit enough to receive it. It requires good performance status and close monitoring.
  • Gemcitabine with nab-paclitaxel — the main alternative, with a different side-effect profile and less stringent fitness requirements.
  • Second-line treatment — decided by what was used first, by how long the response lasted, and by the molecular results; there is no single standard.
  • Radiotherapy — used for local control and for pain in locally advanced disease, and to treat symptomatic deposits such as painful bone metastases. It is not a substitute for systemic treatment in metastatic disease.

Treatment is given in cycles with restaging at defined intervals, and the plan is reviewed rather than simply continued. If the tumour is stable and the patient is tolerating treatment, it continues; if it progresses, the next option is chosen before the patient becomes too unwell to receive it.

Targeted treatment and maintenance

Pancreatic cancer has fewer actionable targets than lung or breast cancer, but testing is worth doing because the findings change treatment for a minority in a way that is not achievable otherwise.

  • PARP inhibitor maintenance — for patients with a germline BRCA1, BRCA2 or PALB2 alteration whose disease has been controlled by platinum-based chemotherapy, continuing a PARP inhibitor afterwards extends the time before the disease progresses.
  • Rare KRAS variants — specific KRAS mutations now have inhibitors in clinical use and in trials, which is a change from the position even a few years ago and makes KRAS testing more than academic.
  • Immune checkpoint inhibitors — reserved for the small group whose tumours are MSI-high or mismatch repair deficient, where the response can be substantial; they are not effective in the ordinary mismatch repair proficient tumour.
  • Fusion-directed therapy — NTRK and NRG1 fusions are rare but matchable, and worth testing for in younger patients and in those with no KRAS mutation.

The honest summary is that most pancreatic cancers have no single dominant target, and the value of testing is concentrated in the minority who do — which is why testing is requested once, early, rather than repeatedly.

Relieving jaundice, pain and weight loss

Supportive treatment is not what happens when active treatment fails. In pancreatic cancer it is frequently the treatment that makes everything else possible, and it deserves to be planned from the beginning:

  • Biliary drainage — a stent placed endoscopically, or a drain through the skin where endoscopy is not possible, to relieve obstructive jaundice. Relieving it improves liver function, appetite and the ability to tolerate chemotherapy.
  • Duodenal obstruction — a tumour that narrows the duodenum may need an endoscopic stent to allow eating, rather than repeated admissions for vomiting.
  • Pain control — the coeliac plexus lies behind the pancreas and can be blocked with an injection at the time of endoscopic ultrasound. It is effective, it reduces opioid requirements, and it is under-used.
  • Pancreatic enzyme replacement — capsules taken with food to replace the enzymes the blocked duct no longer delivers, which addresses the fatty stools and helps weight stabilise.
  • Dietetic and diabetes support — weight loss and glucose control both influence how much treatment a patient can receive, so both are treated as clinical problems rather than as side matters.

Two things make this section different from a list of options. Bile duct drainage and pain control are often needed within weeks of diagnosis, and arranging them early prevents a deterioration that makes later treatment impossible. And because pancreatic surgery and chemotherapy both depend on nutritional reserve, the dietitian is part of the treatment team, not a referral made at the end.

How the decision is actually made

Pancreatic cancer is planned by a multidisciplinary team — surgery, medical oncology, gastroenterology, radiology, pathology, radiotherapy and dietetics — and it is one of the cancers where the meeting changes decisions rather than ratifying them.

  • Resectability is agreed jointly — the surgeon, the radiologist and the oncologist look at the same images together, which is how a borderline case becomes operable or stays locally advanced.
  • The sequence is set before treatment starts — chemotherapy first, surgery first, or systemic treatment alone, with a defined point at which the plan will be reviewed.
  • Molecular results are folded in — the tissue from the needle is what allows BRCA testing and mismatch repair testing, and those results change maintenance treatment later.
  • Supportive care is decided in the same meeting — whether a stent is needed, when a coeliac plexus block should be arranged, and what the nutritional plan is.
  • The plan is written down — patients receive the agreed assessment in writing, including the resectability category and the reasoning, which makes a second opinion a comparison of plans rather than of impressions.

Send complete records — the CT on disc, the cytology, the blood results — and the written assessment is returned within 48 hours of the file being complete, including whether treatment should begin with chemotherapy or with surgery and what would need to change for the answer to change.

Frequently Asked Questions

Why would chemotherapy be given before surgery rather than after?

Because in borderline resectable disease the chemotherapy is not a delay — it is the step that makes the operation possible. The tumour may pull away from the vein it is touching, which allows a clean removal. It also shows how the disease behaves: if it grows during chemotherapy, an operation would not have controlled it either, and the patient has been spared a major procedure that could not have achieved its aim.

Is the Whipple operation always necessary?

Not always, and it depends on where the tumour is. A tumour in the head of the gland requires a pancreaticoduodenectomy. A tumour in the body or tail is treated with a distal pancreatectomy, which is a smaller operation. And if the tumour already encases a major artery or has spread, no operation on the pancreas is performed, because removal in that situation does not improve the outcome while carrying the full risk of the procedure.

Can radiotherapy be used instead of surgery?

It can be used instead of surgery in the sense that it is the local treatment given when surgery is not possible — but it is not equivalent to an operation. Radiotherapy controls the tumour locally for a time and can relieve pain, and it is combined with chemotherapy for locally advanced disease. It cannot remove the tumour, so it does not offer the possibility of cure that a complete resection does.

Patient Stories

Stories from our pancreatic cancer programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

Deciding between chemotherapy first and surgery first?

Send the contrast-enhanced CT on disc, the cytology report and the CA19-9 value. Our hepato-pancreato-biliary multidisciplinary team will settle the resectability category, recommend whether treatment should begin with chemotherapy or with surgery, and return a written assessment within 48 hours.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*